# TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.

> **NCT00650832** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 334 (actual)

## Conditions studied

- HIV

## Interventions

- **DRUG:** TMC114; darunavir; Prezista

## Key facts

- **NCT ID:** NCT00650832
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2005-02
- **Final completion:** 2007-07
- **Target enrollment:** 334 (ACTUAL)
- **Last updated:** 2011-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00650832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00650832, "TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00650832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*